

For personal use only



AGM Presentation

November 2023



Year in review

For personal use only

October 2022

- Announced development of new sensor application in collaboration with Medtronic to assess movement quality of patients with spinal conditions worth A\$195,000

April 2022

- Commenced clinical project with the University of Rochester Medical Center worth A\$100,000 in sponsored research support
- Upgraded flagship ViMove+ product with release of the new “Run Module”

July 2023

- Enhanced Run Module with AI-powered video tracking features

October 2023

- Strengthened leadership team with the appointment of Dr Michael Winlo to the Board of Directors



FY23 Key Operating Metrics

For personal use only

\$1.8m

Sales revenue

\$1.1m

Annualised recurring revenue

\$1.0m

New contracts signed

86%

Gross profit margin

22%

Reduction in opex from FY22¹

~\$538k

As at Sept 2023
(does not include \$400k
Capital raise Nov 2023)

Clear and validated strategy - valuable target markets

Targeting two key valuable markets with attractive growth propositions

For personal use only



Workplace



Clinical



Direct sales channel

- ✓ Contracts with tier one enterprise customers
- ✓ Use data insights to change workplace practices
- ✓ Reduced injuries, higher productivity, improved safety culture



Strategic customers



Growth drivers

- ✓ Staff returning to work in AUS and the US
- ✓ Return to focus on manual handling (post Covid)
- ✓ Increased concern for workplace safety and culture


- ✓ Selling sensors direct to physical therapists (PT), utilising existing reimbursement codes
- ✓ Capture real time assessment data and allow tracking of treatment progress
- ✓ Optimise patient outcomes & rehabilitation

- ✓ Increased adoption of digitised solutions
- ✓ Target large franchise groups in US PT market
- ✓ Scalable and optimised new product offering built on an ISO27001 secure platform

Continuous innovation

Investments into clinical grade product unlocks exciting growth pathways

For personal use only




Lean expense management

Effective cost base reduction leads to a sustainable business model

For personal use only

Operating expenses (A\$m)¹



Cost initiatives

Workforce optimisation

- ✓ Product enhancements driving greater efficiencies
- ✓ Optimised senior management structure

Overhead costs

- ✓ Decreased spend on external consultants
- ✓ Regulatory approvals reduce compliance costs

Operating costs

- ✓ Lower unit cost of sensors and streamlined manufacturing
- ✓ Implemented direct shipping to reduce handling costs

Industry tailwinds supportive of growth

dorsaVi is well placed to capitalise on macroeconomic trends

AI revolution



dorsaVi's early use of AI places the company in a strong position to capitalise on the global shift towards AI adoption

Digital health



Increasing demand for wearable technologies as more patients are recovering outside the hospital and require modes of care that can be remotely monitored

Workplace Safety



Focus on employee well-being leading to greater investment into research and technology to analyse ergonomic activity

For personal use only

Important information and disclaimer

For personal use only

Not financial product advice or offer

This presentation does not constitute an offer of securities or investment, legal, taxation or other advice and the presentation does not take into account your investment objectives, financial situation or particular needs. You are responsible for forming your own opinions and conclusions on such matters and should make your own independent assessment of the information presented. No responsibility is accepted by dorsaVi or any of its respective officers, employees, agents, advisers or associates for any of the information or for any action taken by you on the basis of that information. Any and all use of the information is at your own risk.

Except as required by law, no representation or warranty, express or implied, is made as to the accuracy, completeness or correctness of the information, opinions and conclusions, or as to the reasonableness of any assumption contained in this presentation. By receiving this information and to the extent permitted by law, you release dorsaVi and its respective officers, employees, agents, advisers and associates from any liability (including, without limitation, indirect or consequential loss or damage, or loss or damage arising by negligence) arising as a result of the reliance by you or any other person on anything contained in or omitted from this document or presentation.

The distribution of this Presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this Presentation may not be distributed or released in the United States. Any securities that have been or may be issued by dorsaVi have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which dorsaVi has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws. Refer to the Appendix of this Presentation for further details about international offer restrictions.

Financial Information

All financial information in this Presentation is in Australian dollars (\$) or AUD unless otherwise stated. This Presentation includes certain pro forma financial information. Any such pro forma historical financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of dorsaVi's views on its, nor anyone else's, future financial position and/or performance and does not constitute a forecast. Any pro forma historical financial information has been prepared by dorsaVi in accordance with the measurement and recognition principles, but not the disclosure requirements, prescribed by the Australian Accounting Standards (AAS). In addition, the pro forma financial information in this Presentation does not purport to be in compliance with Article 11 of Regulation S-X of the rules and regulations of the U.S. Securities and Exchange Commission, and such information does not purport to comply with Article 3-05 of Regulation S-X.

Investors should be aware that certain financial measures included in this Presentation are 'non-IFRS financial information' under ASIC Regulatory Guide 230: 'Disclosing non-IFRS financial information' published by ASIC and also 'non-GAAP financial measures' within the meaning of Regulation G under the U.S. Securities Exchange Act of 1934, as amended, and are not recognised under AAS and International Financial Reporting Standards (IFRS). Such non-IFRS financial information/non-GAAP financial measures do not have a standardised meaning prescribed by AAS or IFRS. Therefore, the non-IFRS financial information may not be comparable to similarly titled measures presented by other entities, and should not be construed as an alternative to other financial measures determined in accordance with AAS or IFRS. Although dorsaVi believes these non-IFRS financial measures provide useful information to investors in measuring the financial performance and condition of its business, investors are cautioned not to place undue reliance on any non-IFRS financial information/non-GAAP financial measures included in this Presentation.

Forward-Looking Statements

This document contains or may contain forward-looking statements that are based on dorsaVi management's beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating performance, events or developments that dorsaVi expects or anticipates will occur in the future are forward-looking statements, including without limitation its expectations with respect to dorsaVi's ability to commercialise its products including its estimates of potential revenues, costs, profitability and financial performance; its ability to develop and commercialise new products including its ability to obtain reimbursement for its products; its expectations with respect to the integrity or capabilities of its intellectual property position. dorsaVi's management believe that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. dorsaVi does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. dorsaVi may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Given the current uncertainties regarding the impact of COVID-19 on the trading conditions impacting dorsaVi, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

For personal use only

Contact us

Company

Andrew Ronchi
Director and CEO
T: +61 417 882 267
E: ar@dorsavi.com

Investors

Dean Dribbin
Vesparum Capital
T: +61 3 8582 4800
E: dorsavi@vesparum.com

Unit 3, 11-13 Milgate Street
South Oakleigh, Vic, 3167
www.dorsavi.com

